Comparative effectiveness research priorities at federal agencies: The view from the department of veterans affairs, national institute on aging, and agency for healthcare research and quality

Journal of the American Geriatrics Society

Volumn 58, Issue 6, 2010, Pages 1187-1192

  O'Leary, Timothy J ^a   Slutsky, Jean R ^b   Bernard, Marie A ^c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Comparative effectiveness; Patient outcomes; Research

Indexed keywords

AGING; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; ELDERLY CARE; FUNDING; GOVERNMENT; HEALTH CARE SYSTEM; LAW; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; OUTCOMES RESEARCH; RESEARCH PRIORITY; REVIEW; UNITED STATES; GERIATRICS; HUMAN; ORGANIZATION;

BIOMEDICAL RESEARCH; GERIATRICS; HUMANS; NATIONAL INSTITUTE ON AGING (U.S.); ORGANIZATIONAL OBJECTIVES; UNITED STATES; UNITED STATES AGENCY FOR HEALTHCARE RESEARCH AND QUALITY; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 77953094402     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02939.x     Document Type: Review

References (14)

1. National Institutes of Health: Research Reporting On-line Tools (RePORT). Estimates for Funding for Various Research, Conditions, and Disease Categories (RCDC). Available at Accessed March 6, 2010.
2. A CBO Paper: Research on the Comparative Effectiveness of Medical Treatments. Congress of the United States Congressional Budget Office. Pub. No. 2975, December 2007, p 3. Available at Accessed January 26, 2010.
3. US Food and Drug Administration. About FDA: what we do. Available at Accessed March 16, 2010.
4. Code of Federal Regulations. Title 21, part 314-Applications for FDA approval to market a new drug: Subpart D-FDA action on applications and abbreviated applications. Section 314.125-Refusal to approve an application. Available at Accessed March 16, 2010.
5. Federal Register/Vol. 68, No. 187/Friday, September 26, 2003/Notices. Department of Human Services, Centers for Medicare & Medicaid Services. Medicare Program; Revised Process for Making Medicare National Coverage Determinations.
6. A CBO Paper: Research on the Comparative Effectiveness of Medical Treatments. Congress of the United States Congressional Budget Office. Pub. No. 2975, December 2007, p 4. Available at Accessed January 26, 2010.
7. Borden WE, O'Rourke RA, Toe KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 356 : 1503 1516.
8. IOM (Institute of Medicine). Initial National Priorities for Comparative Effectiveness Research.
9. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and the Congress. June 30, 2009. U.S. Department of Health and Human Services. Federal Coordination Committee.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 : 2981 2997.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288 : 2998 3007.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type II diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
13. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 : 129 139.
14. Shroyer AL, Grover FL, Hattler B et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med 2009 361 : 1827 1837.